Press release as PDF

Stable sales for OLYSIO during the third quarter 2014

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that the global third quarter net sales of OLYSIO® (simeprevir) amounted to 796 MUSD, of which 671 MUSD were sales in the USA.

Medivir’s royalties based on sales for the third quarter are calculated from the highest royalty tier and currency conversion from USD to Euro is based on the YTD exchange rate.
The royalty amounted to 516,4 MSEK (56,2 MEUR).

OLYSIO® global net sales                      Sales in MUSD
Market Q3 2014 Q2 2014 Q1 2014
US 671 725 291
RoW 125 106 63
Total global net sales MUSD 796 831 354

Medivir will publish its third quarter report on November 20, 2014 at 8.30 CET followed by a Conference call for investors, analysts and the media at 14.00 CET. More information about the Conference call / Webcast will be posted at www.Medivir.com

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

Medivir is required under the Securities Markets Act to make the information in this press release public.
The information was submitted for publication at 13.55 CET on 14 October2014.

About Simeprevir (Olysio®)
Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen. Simeprevir efficacy has been established in HCV genotype 1 and HCV genotype 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries.
Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen‐Cilag International NV. Simeprevir was approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis. Simeprevir was approved in September 2013 in Japan, in November 2013 in Canada and the U.S., in March 2014 in Russia and in July 2014 in Mexico and Australia.

In May 2014 simeprevir was granted marketing authorization by the European Commission (EC) for the treatment of adult patients with genotype 1 or genotype 4 chronic HCV. Following the EMA approval, it has so far been made available in several EU countries in conjunction with reimbursement. Simeprevir (Olysio) is marketed under the trade name Sovriad® in Japan and Russia, Galexos™ in Canada and Olysio® in the U.S. and European Union.

About Medivir
Medivir is an emerging and profitable research‐based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals.
Medivir receives royalties from Johnson & Johnson on the global sales of the hepatitis C pharmaceutical, Olysio. In addition, revenues for sales of Olysio in the Nordic region are generated through the company’s own sales and marketing organisation. Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science, targeting different disease areas. The company’s current research and development focus is within infectious diseases, osteoarthritis, neuropathic pain and oncology. Medivir is listed on the Nasdaq OMX Stockholm Mid Cap List.

Page updated 15 maj 2017